Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.

美纳里尼基金会

该基金会成立于 1976 年...

GO TO SITE

美纳里尼在亚太地区

搜索我们的公司

主要品牌

最新动态

September 20 2022

美纳里尼与赛生药业签署独家许可协议 - 在华开发和商业化Vaborem®以治疗耐药菌感染

Read More
August 24 2022

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

Read More
August 11 2022

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Read More
August 02 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Read More
July 22 2022

Australian sports stars shine at XXVI Fair Play Menarini International Awards

Read More